Overview

  • Product nameAnti-MLH1 antibodySee all MLH1 primary antibodies ...
  • Description
    Rabbit polyclonal to MLH1
  • Tested applicationsWB, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Predicted to work with: Horse, Cow, Dog, Chimpanzee, Zebra finch
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 700 to the C-terminus of Human MLH1.

    (Peptide available as ab86630.)

  • Positive control
    • This antibody gave a positive signal in the following lysates: U2OS Whole Cell; Human Thymus Tissue; Mouse Spleen Tissue; Rat Spleen Tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab47703 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 85 kDa (predicted molecular weight: 85 kDa).Can be blocked with Human MLH1 peptide (ab86630).
ICC/IF Use a concentration of 5 µg/ml.

Target

  • FunctionHeterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
  • Tissue specificityColon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
  • Involvement in diseaseDefects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2) [MIM:609310]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
    Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
    Defects in MLH1 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
    Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.
    Defects in MLH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
    Note=Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.
  • Sequence similaritiesBelongs to the DNA mismatch repair mutL/hexB family.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • COCA 2 antibody
    • COCA2 antibody
    • DNA mismatch repair protein Mlh1 antibody
    • FCC 2 antibody
    • FCC2 antibody
    • hMLH 1 antibody
    • hMLH1 antibody
    • HNPCC 2 antibody
    • HNPCC antibody
    • HNPCC2 antibody
    • MGC5172 antibody
    • MLH 1 antibody
    • MLH1 antibody
    • MLH1_HUMAN antibody
    • MutL homolog 1 (E. coli) antibody
    • MutL homolog 1 antibody
    • MutL homolog 1 colon cancer nonpolyposis type 2 antibody
    • MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody
    • MutL protein homolog 1 antibody
    • MutL, E. coli, homolog of, 1 antibody
    see all

Anti-MLH1 antibody images

  • All lanes : Anti-MLH1 antibody (ab47703) at 1 µg/ml

    Lane 1 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
    Lane 2 : Thymus (Human) Tissue Lysate - adult normal tissue (ab30146)

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 85 kDa
    Observed band size : 85 kDa
    Additional bands at : 55 kDa. We are unsure as to the identity of these extra bands.
  • ICC/IF image of ab47703 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab47703, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) Hek293, HepG2 and MCF7 cells at 5µg/ml.
  • All lanes : Anti-MLH1 antibody (ab47703) at 1 µg/ml

    Lane 1 : Spleen (Mouse) Tissue Lysate
    Lane 2 : Spleen (Rat) Tissue Lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) (ab65484) at 1/5000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 85 kDa
    Observed band size : 85 kDa


    Exposure time : 20 minutes

References for Anti-MLH1 antibody (ab47703)

This product has been referenced in:
  • Zhang J  et al. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 78:103-14 (2010). Read more (PubMed: 20357518) »

See 1 Publication for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Specification HeLa
Fixative Paraformaldehyde
Permeabilization Yes - 0.5% Triton-X100 in PBS
Username

Dr. Kirk McManus

Verified customer

Submitted Sep 03 2012

Thank you for your enquiry.

At this time we have no information regarding the use of a ab47703 & ab84909 in MSI.

I'm sorry I could not be of further assistance in this instance. Please contact us again if you have any further qu...

Read More

DISCOUNT CODE: XX

Expiration date: XX
I am very pleased to hear you would like to accept our offer and test ab47703 in chicken. This code will give you 1 free primary antibody before the expiration date. To redeem this offer, please submi...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"